Skip to main content
Premium Trial:

Request an Annual Quote

Biocartis, Janssen Diagnostic Developing PCR-based Ebola Test

NEW YORK (GenomeWeb) – Biocartis announced today that it is developing a blood-based Ebola test in collaboration with Janssen Diagnostics and the Institute for Tropical Medicine in Antwerp.

The Rapid Ebola Virus Triage Test is being designed to run on Biocartis' Idylla real-time PCR-based molecular diagnostics system, which is already CE-IVD marked in Europe. The platform takes approximately 90 minutes to analyze a blood sample and can be operated in both laboratory and field settings, according to the company.

Biocartis said it will initially test the device against synthetic virus samples in Belgium and the US and has registered to run trials in West Africa, where there is currently an Ebola outbreak, to gather additional clinical data on the test.

"This test aims not only to improve the diagnosis of the Ebola virus for hard-pressed healthcare professionals in the field, but to lay the foundations for a better and faster diagnostic infrastructure after the current outbreak has receded, both in this region and around the world," Biocartis CEO Rudi Pauwels said in a statement.

Biocartis and Janssen began working together in early 2011, inking a deal to co-develop assays for the Idylla platform. Under the arrangement, Janssen has the exclusive, worldwide rights to assays for neurological disorders and certain viral infections diseases.

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.